中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2010年
5期
303-306
,共4页
席晨辉%范子义%庄大勇%郑鲁明%段松建%何君美%范西红%贺青卿
席晨輝%範子義%莊大勇%鄭魯明%段鬆建%何君美%範西紅%賀青卿
석신휘%범자의%장대용%정로명%단송건%하군미%범서홍%하청경
乳腺癌%HER-2/neu基因%免疫组织化学%荧光原位杂交
乳腺癌%HER-2/neu基因%免疫組織化學%熒光原位雜交
유선암%HER-2/neu기인%면역조직화학%형광원위잡교
Breast cancer%HER-2/neu gene%Immuno-histochemistry%Fluorescent in situ hybridization
目的 比较免疫组化(IHC)法与荧光原位杂交(FISH)法检测乳腺癌组织HER-2状态,分析二者相关性.方法 应用IHC法与FISH法对56例女性新发乳腺癌行HER-2蛋白表达及基因扩增的检测.结果 56例受试者中HER-2蛋白表达(-)、(+)、(++)、(+++)者分别为9例(16.1%)、29例(51.8%)、11例(19.6%)、7例(12.5%);有26例(46.4%)HER-2基因扩增,30例(53.6%)无扩增.HER-2基因扩增主要表现在HER-2(++)和(+++)中,基因扩增率分别为72 7%和100%.HER-2(+)中有11例(37.9%)出现基因扩增,HER-2(-)中未见基因扩增.两种方法检测结果的阳性率差异有统计学意义(χ2=19.778,P＜0.01).HER-2(-)及HER-2(+++)与FISH结果一致性很好(Kappa=0.969).HER-2(+)及HER-2(++)与FISH结果一致性较差(Kappa=0.271).结论 IHC是HER-2表达初步的筛查方法,HER-2(-)和(+++)者与基因扩增情况有很好的一致性,可直接指导临床治疗.HER-2(+)和(++)者中有部分HER-2基因扩增阳性,如行靶向治疗需进一步行FISH检测.
目的 比較免疫組化(IHC)法與熒光原位雜交(FISH)法檢測乳腺癌組織HER-2狀態,分析二者相關性.方法 應用IHC法與FISH法對56例女性新髮乳腺癌行HER-2蛋白錶達及基因擴增的檢測.結果 56例受試者中HER-2蛋白錶達(-)、(+)、(++)、(+++)者分彆為9例(16.1%)、29例(51.8%)、11例(19.6%)、7例(12.5%);有26例(46.4%)HER-2基因擴增,30例(53.6%)無擴增.HER-2基因擴增主要錶現在HER-2(++)和(+++)中,基因擴增率分彆為72 7%和100%.HER-2(+)中有11例(37.9%)齣現基因擴增,HER-2(-)中未見基因擴增.兩種方法檢測結果的暘性率差異有統計學意義(χ2=19.778,P＜0.01).HER-2(-)及HER-2(+++)與FISH結果一緻性很好(Kappa=0.969).HER-2(+)及HER-2(++)與FISH結果一緻性較差(Kappa=0.271).結論 IHC是HER-2錶達初步的篩查方法,HER-2(-)和(+++)者與基因擴增情況有很好的一緻性,可直接指導臨床治療.HER-2(+)和(++)者中有部分HER-2基因擴增暘性,如行靶嚮治療需進一步行FISH檢測.
목적 비교면역조화(IHC)법여형광원위잡교(FISH)법검측유선암조직HER-2상태,분석이자상관성.방법 응용IHC법여FISH법대56례녀성신발유선암행HER-2단백표체급기인확증적검측.결과 56례수시자중HER-2단백표체(-)、(+)、(++)、(+++)자분별위9례(16.1%)、29례(51.8%)、11례(19.6%)、7례(12.5%);유26례(46.4%)HER-2기인확증,30례(53.6%)무확증.HER-2기인확증주요표현재HER-2(++)화(+++)중,기인확증솔분별위72 7%화100%.HER-2(+)중유11례(37.9%)출현기인확증,HER-2(-)중미견기인확증.량충방법검측결과적양성솔차이유통계학의의(χ2=19.778,P＜0.01).HER-2(-)급HER-2(+++)여FISH결과일치성흔호(Kappa=0.969).HER-2(+)급HER-2(++)여FISH결과일치성교차(Kappa=0.271).결론 IHC시HER-2표체초보적사사방법,HER-2(-)화(+++)자여기인확증정황유흔호적일치성,가직접지도림상치료.HER-2(+)화(++)자중유부분HER-2기인확증양성,여행파향치료수진일보행FISH검측.
Objective To compare HER-2 state in breast cancer tissue deteced by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) and analyze their correlation. Methods HER-2/neu protein expression and gene amplification were detected by FISH and IHC in 56 newly-diagnosed cases of female breast cancer from July 2008 to July 2009. Results Of the 56 patients, HER-2 protein expression (-), (+), (++), (+++) was 9 cases (16.1%), 29 cases (51.8%), 11 cases (19.6%) and 7cases (12.5%) respectively; 26 cases (46.4%) had HER-2 gene amplification while 30 cases (53.6%) didnt have. Type of HER-2 gene amplification was mainly HER-2(++) and HER-2(+++), and according gene amplification rate was 72 7% and 100%. HER-2 (+) gene amplification rate was 37.9 %(11cases) and no gene amplification was found in HER-2(-) tissue. The HER-2 positive rate using two methods had significant difference(χ2=19.778,P<0.01). HER-2(-) and HER-2(+++) had good consistency with the FISH results(Kappa=0.969),but HER-2(+) and HER-2(+ +) were poorly consistent with the FISH results(Kappa=0.271). Conclusions IHC is the preliminary screening method for detection of HER-2 expression. HER-2(-) and HER-2(+++) have good consistency with the gene amplification, and can guide clinical treatment. Some patients with HER-2(+) and HER-2(++) have HER-2 gene amplification. FISH is needed for targeted therapy.
